Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Quick STI tests may boost HIV prevention in teens

NCT ID NCT06844045

First seen Nov 17, 2025 · Last updated Jun 19, 2026 · Updated 29 times

Summary

This study tests whether offering rapid point-of-care testing for gonorrhea and chlamydia helps more teens get HIV testing and PrEP. About 6,460 adolescents aged 16-24 will be compared: some get rapid testing, others get standard lab testing. The goal is to see if same-day results lead to more HIV prevention services.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POINT OF CARE STI TESTING are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's Hospital of Philadelphia

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

point-of-care testing for gonorrhea and chlamydia

What this could lead to

If it works, this could show that rapid STI testing makes it easier for teens to get same-day HIV testing and prevention services.

What could go wrong

This is an early-stage, non-randomized study, so results may not apply to all clinics. The intervention is behavioral, not a drug, so impact may be modest.

Conditions

The condition(s) this trial relates to.

chlamydia infectious disease gonorrhea sexually transmitted disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.